Lv21
124 积分 2023-12-13 加入
G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
4小时前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
2天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
2天前
已完结
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
8天前
已关闭
Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis
9天前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
14天前
已完结
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials
15天前
已完结
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
15天前
已完结
Type 2 diabetes
18天前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
28天前
已完结
皖公网安备34019202002308
